The group’s antisense project is the only game in town for Usher syndrome, but its latest trial is not a slam-dunk.
With results of the full primary analysis now out the spotlight falls on a further 14 as yet unadjudicated Covid-19 cases.
Boehringer says its inhaled antibody could reach the patients IV antibodies cannot, but will be “very happy” if it isn’t needed.
The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.
AZD1222 could be rehabilitated by US pivotal trial data showing efficacy of 79%, with no worries about blood clots.
The group hopes for a better result with a higher dose of its antisense projects, but it also has a back-up plan.
The company’s lead cystic fibrosis asset fails, shifting the focus to the Sanofi-partnered Covid-19 vaccine.